Peer-reviewed version available at Int. J. Environ. Res. Public Health 2018, 15, 1773; doi:10.3390/ijerph15081773

Review article

Vitamin D deficiency in chronic kidney disease: Recent evidence and controversies

Pedro Henrique Franca Gois[1,2]*, Martin Wolley[1,2], Dwarakanathan Ranganathan[1,2] and Antonio Carlos Seguro[3]

[1] Kidney Health Service, Royal Brisbane and Women's Hospital, Herston QLD 4029, Australia; martin.wolley@health.qld.gov.au (M.W.); dwarakanathan.ranganathan@health.qld.gov.au (D.R)
[2] Medical School, University of Queensland, Herston QLD 4029, Australia;
[3] Laboratory of Medical Research-LIM12, Nephrology Department, University of São Paulo School of Medicine, São Paulo, CEP 01246-903, Brazil; trulu@usp.br (A.C.S.)
* Correspondence: pedro.francagois@health.qld.gov.au; Tel.: +61-(07)-3646-8576

Abstract: Vitamin D (VD) is a pro-hormone essential for life in higher animals. It is present in few types of foods and is produced endogenously in the skin by a photochemical reaction. The final step of VD activation occurs in the kidneys involving a second hydroxylation reaction to generate the biologically active metabolite 1,25(OH)$_2$-VD. Extrarenal 1α-hydroxylation has also been described to have an important role in autocrine and paracrine signaling. Vitamin D deficiency (VDD) has been in the spotlight as a major public health-care issue with an estimated prevalence of more than a billion people worldwide. Among individuals with chronic kidney disease (CKD), VDD prevalence has been reported to be as high as 80%. Classically VD plays a pivotal role in calcium and phosphorus homeostasis. Nevertheless, there is a growing body of evidence supporting the importance of VD in many vital nonskeletal biological processes such as endothelial function, renin-angiotensin-aldosterone system modulation, redox balance and innate and adaptive immunity. In individuals with CKD, VDD has been associated with albuminuria, faster progression of kidney disease and increased all-cause mortality. Recent guidelines support VD supplementation in CKD based on extrapolation from cohorts conducted in the general population. In this review, we discuss new insights on the multifactorial pathophysiology of VDD in CKD as well as how it may negatively modulate different organs and systems. We also critically review the latest evidence and controversies of VD monitoring and supplementation in CKD patients.

Keywords: Vitamin D; Vitamin D deficiency; Chronic Kidney Disease; Proteinuria.

1. Introduction

Vitamin D (VD) is a pro-hormone essential for life in higher animals. It is present in few types of foods and is produced endogenously in the skin by a photochemical reaction [1]. There are two major forms of VD, ergocalciferol (VD$_2$) and cholecalciferol (VD$_3$), both sharing similar metabolic pathways [2]. VD$_2$ is most commonly found in vegetable sources and in "fortified" foods [1–3]. VD$_3$ can be found in animal-based foods but is mainly synthesized in the skin by a photolytic conversion of cutaneous 7-dehydroxycholesterol by UV sunlight to form previtamin D$_3$ and subsequently VD$_3$ [4,5].

Regardless of its source, VD$_2$ and VD$_3$ are transported by a VD-binding protein (VDBP) in the liver where they undergo hydroxylation at the carbon 25 position by 25-hydroxylase (also known as CYP2R1) to become 25-hydroxyvitamin D [25(OH)-VD] [6]. 25(OH)-VD is the main circulating form of VD and its plasma levels are routinely measured as a marker of VD status [2]. Although 25(OH)-VD is considered the precursor of the active form 1,25(OH)$_2$-VD, it can also bind to vitamin D receptor (VDR) generating biological responses [7].

Peer-reviewed version available at Int. J. Environ. Res. Public Health 2018, 15, 1773; doi:10.3390/ijerph15081773

The final step of VD activation involves a second hydroxylation in which the enzyme 1α-hydroxylase (also known as CYP27B1) converts 25(OH)-VD in 1,25$(OH)_2$-VD (Figure 1) [8]. Under physiological conditions, 1,25$(OH)_2$-VD is mainly synthesized in the kidneys but in specific conditions, such as pregnancy, chronic renal failure, rheumatoid arthritis and granulomatous diseases, other cell types can also contribute to its circulating levels [6]. Moreover, there is an increasing body of evidence about the pivotal role of extra-renal 1α-hydroxylation for autocrine and paracrine signaling [9–11]. Numerous studies have shown 1-α-hydroxylase activity in many tissues including placenta/decidua, pancreas, colon, vasculature, breast and ovary where it may contribute to tissue function, cell proliferation and immunoregulation [9]. Therefore, the importance of VD in many biological processes transcend calcium and phosphate homeostasis.



Figure 1. Vitamin D activation and metabolism. Adapted from Gois et al [3].

There is no absolute consensus about the definition of VD sufficiency. According to many experts, serum 25(OH)-VD level should be equal or greater than 75 nmol/L (30 ng/mL) [12]. VD insufficiency (VDI) is defined as a serum 25(OH)-VD level between 50 and 74 nmol/L (20–29 ng/mL), whereas VD deficiency (VDD) is recognized as 25(OH)-VD levels of less than 50 nmol/L (20 ng/mL)

[12]. Despite of these definitions, many prevalence studies have employed different cut-offs for VDD, thus causing uncertainty about the magnitude of the problem [13–15].

On the other hand, the upper normal limit of 25(OH)-VD has been a matter of discussion. Excessive sun exposure has never been reported as a cause of VD intoxication [12]. The highest VD level obtained by sunlight exposure was 225 nmol/L reported in a farmer in Puerto Rico [16], whilst individuals exposed to artificial UVB source showed increased VD level as high as 273.6 nmol/L [17]. VD intoxication can be defined as 25(OH)-VD > 150 ng/ml in combination with hypercalcemia, hypercalciuria and frequently hyperphosphatemia [12]. In fact, 25(OH)-VD levels above 125–150 nmol/L should be avoided, as they might be associated with increased risk of intoxication [18].

In individuals with CKD, VDD is highly prevalent and has been associated with albuminuria, faster progression of kidney disease and increased all-cause mortality [19–21]. Recent guidelines support 25(OH)-VD supplementation in CKD based on extrapolation from cohorts drawn from the general population [22–25]. In this review, we discuss new insights on the multifactorial pathophysiology of VDD in CKD as well as how it may negatively modulate different organs and systems. We also critically review the latest evidence and controversies of 25(OH)-VD monitoring and supplementation in CKD patients.

2. VD deficiency in CKD: prevalence and contributing factors

In the general population, VDD is a well-recognized public health problem worldwide with prevalence ranging from 20% and 100% [3,26,27]. Among the most vulnerable to VDD are the elderly, people living in higher latitudes, people with darker skin, obese individuals and patients with CKD [28].

Several studies have demonstrated that individuals with CKD are at high risk of VDD [29–32]. Gonzalez et al. reported that 97% of the patients on hemodialysis presented inadequate levels of 25(OH)-VD [30]. In a cross-sectional analysis of a cohort study including 1056 United States dialysis units, Bhan et al. showed that 79% and 57% out of 908 individuals on chronic hemodialysis (HD) had 25(OH)-VD levels of <30 and <20 ng/mL, respectively [33]. Hypoalbuminemia, black color and dialysis initiation during the winter are strong predictors of VDD, whereas VDD was universal in patients presenting with all these three predictors [33]. Furthermore, the prevalence of VDD among patients with stage 3 and stage 4 CKD (not yet on dialysis) was studied in a multi-centre cohort from 12 geographically diverse regions of the United States [34]. Strikingly, the investigators found that only 29% and 17% of patients respectively with stage 3 and stage 4 CKD had sufficient 25(OH)-VD levels [34].

Although 25(OH)-VD levels start to decrease in individuals with CKD stage 2, inadequate levels can be found in all stages of CKD [30,34–36]. Many factors have been implicated in the high prevalence of VDD among CKD patients.

Patients with CKD, especially on HD, are likely to have less sunlight exposure [35,37]. Del Valle et al. showed that 84% percent of the HD patients with VDD had inadequate sunlight exposure [37]. Uremia may also blunt the response of plasma VD to UVB irradiation [38]. Chronic HD patients exhibited a lower VD response than normal individuals when exposed to a physiologically equivalent dose of UVB [38]. Furthermore, hyperpigmentation, one of the most common cutaneous manifestations in patients undergoing HD, may play an additional role in the impaired endogenous VD synthesis [39,35].

Nutritional factors may also contribute to suboptimal 25(OH)-VD status in CKD. Patients with CKD frequently have low food intake due numerous reasons such as reduced appetite, uremic-related gastrointestinal symptoms and dietary restrictions, i.e. low protein (especially in those on conservative management) and low phosphate diet [40–42]. Uremia might be associated with impaired gastrointestinal absorption of VD. Vaziri et al. showed using an in vivo perfusion technique that uremic rats had a significantly lower rate of jejunal absorption of labeled VD_3 compared to control animals [43]. Nevertheless, the authors did not provide any evidence of the potential mechanisms involved in the uremic impairment of VD gastrointestinal absorption and these results are yet to be translated to humans.

Peer-reviewed version available at Int. J. Environ. Res. Public Health 2018, 15, 1773; doi:10.3390/ijerph15081773

Proteinuria has also been described as a contributing factor in the pathogenesis of VDD [2,44]. The 58 kDa VDBP is an alpha globulin that carries more than 85% of the circulating 25(OH)-VD. Complexes of VDBP and 25(OH)-VD are filtered in the glomerulus allowing transport to the proximal tubule, where a receptor-mediated reabsorption occurs at the level of the brush border involving megalin and cubilin (Figure 2a) [45,46]. Patients with proteinuria usually present with increased urinary excretion of VDBP but might also show impaired megalin and cubilin mediated protein reuptake in the proximal tubules [47,48]. Leheste et al. showed that inactivation of the megalin gene in mice lead to increased urinary excretion of VDBP, VDD, hypocalcemia and osteomalacia [49]. In humans, increased urinary excretion of megalin and cubilin have been reported in diabetes and IgA nephropathy [46,48,50]. Megalin and cubilin shedding therefore might contribute to VDD in the setting of CKD and proteinuria (Figure 2b).



Figure 2. Representation of the tandem function of megalin and cubilin in renal uptake of 25(OH)-VD. (a) Filtered complexes of vitamin D binding protein (VDBP) and 25(OH)-VD are endocytosed by the proximal tubular epithelium via an endocytic receptor-mediated pathway recognizing VDBP. The VDBP is degraded in the lysosomes releasing 25(OH)-VD which is either secreted or hydroxylated in the mitochondria to $1,25(OH)_2$-VD. Both 25(OH)-VD and $1,25(OH)_2$-VD reenter the circulation bound to VDBP. (b) Postulated megalin and cubilin shedding in CKD perpetuating VDD with subsequent lower 25(OH)-VD reuptake and intracrine $1,25(OH)_2$-VD production in the renal proximal tubules.

Serum levels of 25(OH)-VD were found to decline progressively with time in patients on peritoneal dialysis (PD) [51]. Some authors reported lower levels of 25(OH)-VD in PD patients compared to those on HD [52,53]. Gokal et al. reported a mean level of 2 nmol/L of 25(OH)-VD in the

Peer-reviewed version available at Int. J. Environ. Res. Public Health 2018, 15, 1773; doi:10.3390/ijerph15081773

PD effluent [51]. VDBP has been also detected in peritoneal dialysate [54,55]. Therefore, patients on PD are at particularly high risk for VDD given the increased loss of both 25(OH)-VD and VDBP through the peritoneal effluent [54–56].

3. VD: non-classical effects

There is a growing body of evidence supporting the importance of VD in many vital nonskeletal biological processes, such as endothelial function, renin-angiotensin-aldosterone system regulation, redox balance, innate and adaptive immunity (Figure 3). These are known as the non-classical effects of the VD.



Figure 3. Schematic model of the classical and nonclassical effects of vitamin D. 25(OH)-VD and $1,25(OH)_2$-VD circulate mainly bound to the vitamin D binding protein (VDBP). $1,25(OH)_2$-VD endocrine effects are represented on the right. Different types of cells can present the machinery for 25(OH)-VD activation (left). $1,25(OH)_2$-VD in an autocrine and paracrine fashion regulate the transcription of pivotal proteins involved in several biological processes (left).

3.1. VD and endothelial function

A number of studies have described an association between low 25(OH)-VD levels and endothelial dysfunction [57–60]. Carrara et al. prospectively compared 33 patients with essential hypertension and normal 25(OH)-VD levels to 33 patients with essential hypertension and VDD who underwent 8 weeks of VD supplementation. The VDD subgroup had a significant increase in flow-mediated dilation (FMD) of the brachial artery, an important research tool for assessment of endothelial function in vivo [58]. However, in a systematic review only two out of ten randomized clinical trials (RCTs) reported that VD supplementation ameliorated FMD [60].

3.2. VD and the renin-angiotensin-aldosterone system

Peer-reviewed version available at Int. J. Environ. Res. Public Health 2018, 15, 1773; doi:10.3390/ijerph15081773

Vitamin D has also been implicated as an agent which can modulate the renin-angiotensin-aldosterone system (RAAS), and therefore which may influence blood pressure and cardiovascular disease. Evidence for this interaction comes from animal models, molecular studies and clinical data.

In one animal study vitamin D receptor null mice were generated, and demonstrated upregulation of renin and angiotensin II, as well as significant hypertension, increased water intake and increased left ventricular mass compared to wild type animals [61]. Further supporting these findings $1,25(OH)_2$-VD supplementation suppressed renin production in a separate group of wild type animals. Other studies have also demonstrated that paricalcitol supplementation decreases renin and renin receptor expression in animal models of CKD [62]. The mechanism by which this interaction occurs is not yet completely elucidated, but the VDR appears to be able to interact directly with elements of the intracellular complex which promotes pro-renin transcription when in a $1,25(OH)_2$-VD ligand bound form [63]. The interaction has the effect of suppressing renin gene expression, thus suggesting a plausible mechanism.

Whilst these data suggest a role for VD in RAAS regulation, human data linking VDD with hypertension as an end-point of RAAS activation have been mixed. Seasonal and regional blood pressure trends suggest a relationship between UV exposure and hypertension, and cross-sectional studies have demonstrated that VD levels correlate with hypertension prevalence, supporting a VD-RAAS link [64]. However, the largest meta-analysis summarized 46 prospective trials and suggested no effects of 25(OH)-VD supplementation on blood pressure [65]. This does not completely exclude a role for VD in modulation of the RAAS but suggests that the effect may be small and possibly subclinical. Concerns about heterogeneous methods of 25(OH)-VD supplementation, variable achieved 25(OH)-VD levels and variable levels of baseline VDD in the existing trials have caused some uncertainty however and several trials are ongoing.

3.3. VD and redox balance

Low levels of 25(OH)-VD have been associated with increased markers of oxidative stress. In different experimental models, VD deficient animals showed increased thiobarbituric acid reactive substances (TBARS) and decreased glutathione (GSH) levels, respectively a biomarker of oxidative stress and a major endogenous antioxidant [66–68]. Furthermore, human observational studies have shown an inverse relationship between 25(OH)-VD levels and reactive oxygen species [57,69]. Despite these promising results, further clinical studies need to be undertaken to verify whether there is a beneficial effect of VD supplementation on redox balance in subjects with low 25(OH)-VD levels.

3.4. VD and the immune system

Previous in vitro studies highlighted the monocytes and macrophages as one of the first non-renal cells with the ability not only to synthesize $1,25(OH)_2$-VD but also to upregulate the expression of 1α-hydroxylase [9,10]. Once in the monocytes, 25(OH)-VD is converted to active $1,25(OH)_2$-VD by mitochondrial 1-α-hydroxylase and binds to cytoplasmic VDR, thereby acting as a transcription factor for antibacterial peptides such as cathelicidin and beta-defensin 4A. [3,70,71]. More recently, the machinery for VD activation was also observed in other antigen-presenting cells such as dendritic cells [10,72].

$1,25(OH)_2$-VD may also have an anti-inflammatory effect in human T cells [73]. $1,25(OH)_2$-VD has been reported to reduce the expression of the nuclear factor κB (NFκB). In addition, $1,25(OH)_2$-VD may promote a shift in the T helper (Th) cell response from Th1 to Th2, subsequently reducing Th1-mediated tissue damage and increasing the production of Th2 immunomodulatory cytokines [74,75]. Moreover, some studies have reported expression of VDR, 1α-hydroxylase and 24-hydroxylase in human B cells [75,76]. $1,25(OH)_2$-VD may inhibit the differentiation of B cells into plasma cells, thus modulating the production of antibodies [74,75].

4. VD and CKD: human studies

4.1. Bone mineral disease

Peer-reviewed version available at Int. J. Environ. Res. Public Health 2018, 15, 1773; doi:10.3390/ijerph15081773

The inverse correlation between 25(OH)-VD levels and parathyroid hormone (PTH) has been demonstrated across virtually all stages of CKD [20,77,78]. The prevalence of secondary hyperparathyroidism almost doubled when non-dialysis patients presented with 25(OH)-VD ≤ 20 ng/ml compared to those with levels > 20 ng/ml [29]. In addition, PTH levels seem to plateau when 25(OH)-VD is greater than 30 ng/ml [29].

A systematic review with meta-analysis of observational and randomized studies showed a significant decline in PTH levels with 25(OH)-VD supplementation [79]. Similar results were obtained when patients with CKD received active VD analogs [80,81]. Indeed, treatment with either 25(OH)-VD or active VD analogs induced similar responses on PTH in patients with CKD stage 3-4 and hyperparathyroidism [82]. These results suggest a potential additive effect of 25(OH)-VD and active VD analogs on renal hyperparathyroidism [82].

Low 25(OH)-VD has been linked with increased bone turnover and decreased bone mineral density (BMD) in patients with CKD. In a cohort study including 1,026 non-dialysis patients across all CKD stages, Ureña-Torres et al. showed that 25(OH)-VD ≤ 15 ng/ml was associated with high serum bone-specific alkaline phosphatase (BALP) and C-terminal cross-linked collagen type I telopeptides (CTX), both circulating bone remodeling biomarkers [83]. Similar results were reported by Yadav et al. who found that 25(OH)-VD supplementation reduced PTH, BAP and CTX in a randomized, double blind, placebo-controlled trial including 117 patients with CKD 3-4 [84]. 25(OH)-VD levels ≤ 20 ng/ml were also associated with lower BMD at the femur neck and total hip in individuals with CKD stages 3-4 in a Korean populational cohort [85].

25(OH)-VD may hold a direct and independent role on bone formation and mineralization. Coen et al. retrospectively analyzed bone hystomorphometry and histodynamic for different levels of 25(OH)-VD in a cohort of 104 patients on hemodialysis for more than 12 months [86]. The investigators found that 25(OH)-VD < 20 ng/mL was associated with relatively lower bone turnover, whereas histologic evidence of a mineralization defect was only found when VDD was accompanied by elevated PTH [86]. Moreover, patients on HD have twice the risk of symptomatic bone fracture compared to renal transplant patients [87]. Low 25(OH)-VD has also been associated with muscle weakness and risk of falls in patients with end stage renal failure but the evidence to support these associations is still limited to small observational studies [88,89].

Overall, despite the potential benefits of 25(OH)-VD on biochemical markers of mineral metabolism, there is insufficient RCT data available showing unequivocal benefits of supplementation on muscle strength, risk of falls and prevention of fractures in individuals with CKD.

4.2. Albuminuria

Several recent observational studies have highlighted the importance of 25(OH)-VD in areas outside of traditional bone and mineral metabolism. A cross-sectional analysis of the Third National Health and Nutrition Examination Survey (NHANES III) revealed a progressively higher prevalence of albuminuria with decreasing 25(OH)-VD levels in a representative sample of the US population [19]. These results supported the findings of previous studies enrolling diabetic patients in Italy and Japan [90,91]. In Australia, Damasiewicz et al. conducted a prospective study including 6,180 adults with normal renal function at baseline from the Australian Diabetes, Obesity and Lifestyle (AusDiab) study [92]. This large population-based cohort with two follow up phases (at baseline and 5-year) showed that individuals with 25(OH)-VD levels < 15 ng/mL had increased incidence of albuminuria defined as spot urine albumin-creatinine ratio ≥ 2.5 mg/mmol for men and ≥ 3.5 mg/mmol for women [92]. There was a consensus among these studies around the stepwise increase in the prevalence of albuminuria with decreasing 25(OH)-VD levels, however, a clear cutoff point could not be determined.

VD has been shown to suppress the transcription of renin, inhibiting the RAAS and ultimately leading to a reduction in proteinuria through hemodynamic and non-hemodynamic pathways [61,93–95]. VD may also modulate oxidative stress and inflammation reducing fibroblast activation and interstitial inflammation [66,67,69,96] Moreover, CKD progression and lower expression of

Peer-reviewed version available at Int. J. Environ. Res. Public Health 2018, 15, 1773; doi:10.3390/ijerph15081773

megalin have been associated with lower 25(OH)-VD reuptake and therefore reducing intracrine 1,25(OH)$_2$-VD production in the renal proximal tubules (Figure 2b) [47,48,97]. On the other hand, increasing levels of proteinuria may perpetuate VDD. Altogether, there seems to be a synergistic interplay between VDD and CKD leading to a vicious cycle for progressive deterioration of renal function.

Molina et al. published a well-designed single-centre, controlled trial enrolling individuals with CKD 3-4 and persistent albuminuria. Patients were assigned to receive 666 IU of VD$_3$ daily, regardless of the 25(OH)-VD levels, when the PTH was above the expected range for the stage of CKD. Fifty patients were allocated to the intervention group and 51 patients received no intervention. Despite of the small dose of VD$_3$, the authors found a 53% reduction in the urine albumin:creatinine ratio after six months of VD$_3$ treatment [98]. Similarly, Kim et al. reported an anti-proteinuric effect of VD$_3$ in patients with concomitant diabetes, CKD stage 2-4 and low 25(OH)-VD in a small observational study [99]. Nevertheless, no RCT assessing the effects of 25(OH)-VD supplementation on albuminuria has been published thus far. We identified one ongoing study (ClinicalTrials.gov identifier NCT01029002) enrolling 75 patients with CKD stages 3-4 to receive either VD$_2$ or placebo for the primary outcome change in the proteinuria status.

4.3. CKD Progression and Mortality

Recently many observational studies have examined the association between lower 25(OH)-VD effects, CKD progression and mortality. Ravani et al. followed up 168 consecutive new referrals to a CKD clinic over a period of 6 years. CKD stages ranged from 2 to 5 pre-dialysis and most patients had stage 3 and stage 4 CKD. 25(OH)-VD levels predicted progression to dialysis and death in crude analysis and in multiple regression models [20]. Similarly, Barreto et al. conducted a prospective study including 140 CKD patients from stage 2 to 5. The authors aimed to investigate the association between VD levels, vascular calcification, endothelial function and mortality. Although there was an association between 25(OH)-VD levels and mortality, the investigators did not find significant correlation between 25(OH)-VD, aortic calcification and pulse wave velocity – a surrogate marker of endothelial function [36]. Moreover, Wolf et al. performed a cross-sectional analysis of 825 consecutive incident hemodialysis patients across 569 hemodialysis centres in 37 states in the USA [21]. Patients who died within 90 days of initiating dialysis and where compared with those who survived for at least 90 days. Individuals presenting with 25(OH)-VD < 10 ng/mL were at significantly increased risk of all-cause and cardio-vascular mortality compared to subjects with 25(OH)-VD > 30 ng/mL, whilst subjects with 25(OH)-VD levels 10-30 ng/mL showed mixed results after multivariate adjustments [21].

Altogether, despite the observational studies highlighting the role of VDD as a potential risk factor for progression of CKD and mortality, we did not identify any RCT aiming to verify whether there is a beneficial effect of 25(OH)-VD supplementation on these outcomes.

5. VD and CKD: current guidelines

Both the Kidney Disease Outcomes Quality Initiative (KDOQI) and Kidney Disease Improving Global Outcomes (KDIGO) experts recommend checking and supplementing low serum 25(OH)-VD levels in CKD and dialysis patients [22,23]. In the most recent update of the KDIGO guidelines on bone mineral disorder, it is suggested based on low quality evidence that patients with CKD Stage 1-5 have 25(OH)-VD levels measured, and repeated testing should be individualized according to baseline values and interventions [22]. Nevertheless, there was no clear suggestion on how frequent 25(OH)-VD levels should be reviewed [22].

With respect to the recommended dietary allowance of VD in the general population, the institute of medicine from the US and Canada recommended that adults up to the age of 70 years require 600 IU/d of VD, whereas adults 71 years and older require 800 IU/d [100]. These recommendations cover the needs of >97.5% of population and assume minimal or no sun exposure, thus providing further safety for individuals with lower endogenous synthesis of VD [100].

Current guidelines suggest that patients with CKD Stages 1-5 and VDD or VDI should receive supplementation using the same strategies as recommended for the general population [22,23,101]. However, even for the general population the optimal dosage of supplementation varies among the main guidelines. The KDOQI suggests 1,000-2,000 IU/d of VD_3 for VD repletion but acknowledges that patients with CKD may require a more aggressive therapeutic plan [23]. The National Institute for Clinical Excellence (NICE) in the UK suggests that people aged ≥ 65 years who are not exposed to much sun should take 400 IU of VD_3 daily, nevertheless, this guideline did not address VD supplementation in individuals with VDD or VDI [24]. In Australia and New Zealand, the Kidney Health Australia-Caring for Australasians with Renal Impairment (KHA-CARI) do not suggest any specific dosage for VD repletion [101].

Another matter of debate is around which form of VD should be used. VD_2 and VD_3 undergo identical hydroxylation processes and in theory are equally used by the body to generate 1,25(OH)$_2$-VD [102]. In fact, their chemical structure only differs in the side chains (Figure 1) [103]. Armas et al. compared the potency of a single dose of 50,000 IU VD_2 and VD_3 in 30 healthy subjects. Both VD analogues produced similar initial increments in serum 25(OH)-VD but individuals treated with VD_3 had a more sustained response with a 3-fold difference in the area under the curve on the 28th day [104]. Several theories have been proposed to explain the difference between the two calciferols. VD_3 might have a higher affinity to both VDR and 25-hydroxylase [105,106]. Other studies have suggested a lesser affinity of VD_2 for DBP compared to VD_3 resulting in higher clearance and subsequently a shorter circulating half-life [107–109]. Recently, a meta-analysis including seven heterogeneous studies indicated that regardless of the dosage, frequency or administration (oral or intramuscular), VD_3 was more effective at raising serum 25(OH)-VD concentrations compared to VD_2 [110]. Four studies that applied bolus doses also favored VD_3 over VD_2, whereas there was no statistical difference between VD_3 and VD_2 in the pulled data from studies that used daily supplementation [110]. Although VD_3 may be more effective than VD_2, clinicians should ultimately use the presentation commercially available in the context of their clinical practice. For instance, VD_2 is mostly used in the United States, whilst in other countries, such as Australia and Brazil, VD_3 is the most common presentation.

6. Conclusions

In summary, the studies reviewed here highlight the potential role of VD beyond bone mineral disease in patients with CKD. Currently the strongest available evidence supports 25(OH)-VD supplementation aiming to control secondary hyperparathyroidism in CKD patients. Despite of the striking observational data showing the association between lower levels of 25(OH)-VD and various deleterious outcomes (such as low bone turnover, risk of falls and factures, albuminuria, progression of CKD and mortality), there is still a lack of RCTs supporting the potential beneficial effects of supplementation. Many questions remain unanswered regarding the dosing, timing of administration and type of VD analogues in patients with CKD. In addition, the current guidelines are subject to criticism for being mainly opinion-based and derived from observational data. However, given the low-cost and high safety profile, patients with CKD might benefit from 25(OH)-VD supplementation in the setting of VDD and VDI. Although doses of up to 4,000 IU of VD_3 are considered safe for the general population [111], we recommend caution in renal patients specially in those who are on calcium-containing phosphate binder and/or on active VD analogues.

Author Contributions: All authors have contributed substantially to the preparation of this review.

Funding: This review received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Vitamin, D. The British Dietetic Association (BDA) Food Fact Sheet. Available online: https://www.bda.uk.com/foodfacts/VitaminD.pdf (accessed on 17 July 2018).
2. Jean, G.; Souberbielle, J. C.; Chazot, C. Vitamin D in chronic kidney disease and dialysis patients. Nutrients 2017, 9, 328.
3. Gois, P. H. F.; Ferreira, D.; Olenski, S.; Seguro, A. C. Vitamin D and infectious diseases: Simple bystander or contributing factor? Nutrients 2017, 9, E651.
4. Deluca, H. History of the discovery of vitamin D and its active metabolites. Bonekey Rep. 2014, 3, 479.
5. Holick, M. F.; Frommer, J. E.; McNeill, S. C.; Richtand, N. M.; Henley, J. W.; Potts, J. T. Photometabolism of 7-dehydrocholesterol to previtamin D3 in skin. Biochem. Biophys. Res. Commun. 1977, 76, 107–14.
6. Dusso, A. S.; Brown, A. J.; Slatopolsky, E. Vitamin D. Am J Physiol Ren. Physiol 2005, 289, F8--F28.
7. Lou, Y. R.; Molnár, F.; Peräkylä, M.; Qiao, S.; Kalueff, A. V.; St-Arnaud, R.; Carlberg, C.; Tuohimaa, P. 25-Hydroxyvitamin D3is an agonistic vitamin D receptor ligand. J. Steroid Biochem. Mol. Biol. 2010, 118, 162–170.
8. Fraser, D. R.; Kodicek, E. Unique biosynthesis by kidney of a biological active vitamin D metabolite. Nature 1970, 228, 764–6.
9. Townsend, K.; Evans, K. N.; Campbell, M. J.; Colston, K. W.; Adams, J. S.; Hewison, M. Biological actions of extra-renal 25-hydroxyvitamin D-1α-hydroxylase and implications for chemoprevention and treatment. J. Steroid Biochem. Mol. Biol. 2005, 97, 103–109.
10. Hewison, M.; Freeman, L.; Hughes, S. V; Evans, K. N.; Bland, R.; Eliopoulos, A. G.; Kilby, M. D.; Moss, P. A. H.; Chakraverty, R. Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J. Immunol. 2003, 170, 5382–90.
11. Hewison, M.; Zehnder, D.; Chakraverty, R.; Adams, J. S. Vitamin D and barrier function: a novel role for extra-renal 1 alpha-hydroxylase. Mol. Cell. Endocrinol. 2004, 215, 31–8.
12. Holick, M. F. Vitamin D Status: Measurement, Interpretation, and Clinical Application. Ann. Epidemiol. 2009, 19, 73–78.
13. Nowson, C. A.; McGrath, J. J.; Ebeling, P. R.; Haikerwal, A.; Daly, R. M.; Sanders, K. M.; Seibel, M. J.; Mason, R. S. Vitamin D and health in adults in Australia and New Zealand: a position statement. Med. J. Aust. 2012, 196, 686–687.
14. Unger, M. D.; Cuppari, L.; Titan, S. M.; Magalhães, M. C. T.; Sassaki, A. L.; dos Reis, L. M.; Jorgetti, V.; Moysés, R. M. A. Vitamin D status in a sunny country: Where has the sun gone? Clin. Nutr. 2010, 29, 784–788.
15. Hossein-nezhad, A.; Holick, M. F. Vitamin D for Health: A Global Perspective. Mayo Clin. Proc. 2013, 88, 720–755.
16. Alshahrani, F.; Aljohani, N. Vitamin D: Deficiency, sufficiency and toxicity. Nutrients 2013, 5, 3605-16.
17. Krause, R.; Buhring, M.; Hopfenmuller, W.; Holick, M. F.; Sharma, A. M. Ultraviolet B and blood pressure. Lancet 1998, 352, 709-10.
18. Vitamin D — Health Professional Fact Sheet. Available online: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/ (accessed on 17 July 2018).
19. de Boer, I. H.; Ioannou, G. N.; Kestenbaum, B.; Brunzell, J. D.; Weiss, N. S. 25-Hydroxyvitamin D Levels and Albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am. J. Kidney Dis. 2007, 50, 69–77.
20. Ravani, P.; Malberti, F.; Tripepi, G.; Pecchini, P.; Cutrupi, S.; Pizzini, P.; Mallamaci, F.; Zoccali, C. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int. 2009, 75, 88–95.
21. Wolf, M.; Shah, A.; Gutierrez, O.; Ankers, E.; Monroy, M.; Tamez, H.; Steele, D.; Chang, Y.; Camargo, C. A.; Tonelli, M.; Thadhani, R. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007, 72, 1004–1013.
22. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention , and Treatment of Chronic Kidney Disease – Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl. 2017, 7, 1–59.
23. National Kidney Foundation Evaluation and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). 2010, 25, 1–11.
24. National Institute for Health and Care Excellence. Vitamin D: implementation of existing guidance to prevent deficiency. Available online: https://www.nice.org.uk/guidance/ph56/resources/implementing-vitamin-d-guidance-draft-guideline2 (accessed on 17 July 2018).

25. Elder, G.; Faull, R.; Branley, P.; Hawley, C.; Caring for Australasians with Renal Impairment (CARI) The CARI guidelines. Management of bone disease, calcium, phosphate and parathyroid hormone. Nephrology (Carlton). 2006, 11 Suppl 1, S230-61.
26. Mithal, A.; Wahl, D. A.; Bonjour, J. P.; Burckhardt, P.; Dawson-Hughes, B.; Eisman, J. A.; El-Hajj Fuleihan, G.; Josse, R. G.; Lips, P.; Morales-Torres, J. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos. Int. 2009, 20, 1807–1820.
27. Holick, M. F. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin. Proc. 2006, 81, 353–373.
28. Bischoff-ferrari, H. A.; Giovannucci, E.; Willett, W. C.; Dietrich, T.; Dawson-hughes, B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006, 84, 18-28.
29. Holick, M. Vitamin D for Health and In Chronic Kidney Disease. Semin Dial 2005, 8, 266–275.
30. González, E. A.; Sachdeva, A.; Oliver, D. A.; Martin, K. J. Vitamin D insufficiency and deficiency in chronic kidney disease: A single center observational study. Am. J. Nephrol. 2004, 24, 503–510.
31. Fournier, A.; Fardellone, P.; Achard, J. M.; Ghazali, A.; Pruna, A.; El Esper, N.; Morinière, P. Importance of vitamin D repletion in uraemia. Nephrol. Dial. Transplant 1999, 14, 819–23.
32. Eknoyan, G.; Levin, A.; Levin, N. W. Bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 2003, 42, 1–201.
33. Bhan, I.; Burnett-Bowie, S. A. M.; Ye, J.; Tonelli, M.; Thadhani, R. Clinical measures identify vitamin D deficiency in dialysis. Clin. J. Am. Soc. Nephrol. 2010, 5, 460–467.
34. LaClair, R. E.; Hellman, R. N.; Karp, S. L.; Kraus, M.; Ofner, S.; Li, Q.; Graves, K. L.; Moe, S. M. Prevalence of calcidiol deficiency in CKD: A cross-sectional study across latitudes in the United States. Am. J. Kidney Dis. 2005, 45, 1026–1033.
35. Nigwekar, S. U.; Bhan, I.; Thadhani, R. Ergocalciferol and cholecalciferol in CKD. Am. J. Kidney Dis. 2012, 60, 139–156.
36. Barreto, D. V.; Barreto, F. C.; Liabeuf, S.; Temmar, M.; Boitte, F.; Choukroun, G.; Fournier, A.; Massy, Z. A. Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009, 4, 1128–1135.
37. Del Valle, E.; Negri, A. L.; Aguirre, C.; Fradinger, E.; Zanchetta, J. R. Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial Int 2007, 11, 315–321.
38. Jacob, A. I.; Sallman, A.; Santiz, Z.; Hollis, B. W. Defective photoproduction of cholecalciferol in normal and uremic humans. J Nutr 1984, 114, 1313–1319.
39. Kolla, P. K.; Desai, M.; Pathapati, R. M.; Mastan Valli, B.; Pentyala, S.; Madhusudhan Reddy, G.; Vijaya Mohan Rao, A. Cutaneous Manifestations in Patients with Chronic Kidney Disease on Maintenance Hemodialysis. ISRN Dermatol. 2012, 2012, 1–4.
40. Cuppari, L.; Garcia-Lopes, M. G. Hypovitaminosis D in Chronic Kidney Disease Patients: Prevalence and Treatment. J. Ren. Nutr. 2009, 19, 38–43.
41. Rhee, C. M.; Ahmadi, S.-F.; Kovesdy, C. P.; Kalantar-Zadeh, K. Low-protein diet for conservative management of chronic kidney disease: a systematic review and meta-analysis of controlled trials. J. Cachexia. Sarcopenia Muscle 2017, 235–245.
42. Cano, A. E.; Neil, A. K.; Kang, J.-Y.; Barnabas, A.; Eastwood, J. B.; Nelson, S. R.; Hartley, I.; Maxwell, D. Gastrointestinal Symptoms in Patients with End-Stage Renal Disease Undergoing Treatment by Hemodialysis or Peritoneal Dialysis. Am. J. Gastroenterol. 2007, 102, 1990–1997.
43. Vaziri, N. D.; Hollander, D.; Hung, E. K.; Vo, M.; Dadufalza, L. Impaired intestinal absorption of vitamin D3 in azotemic rats. Am. J. Clin. Nutr. 1983, 37, 403–406.
44. Caravaca-Fontán, F.; Gonzales-Candia, B.; Luna, E.; Caravaca, F. Relative importance of the determinants of serum levels of 25-hydroxy vitamin D in patients with chronic kidney disease. Nefrologia. 2016, 36, 510-516.
45. Kalousova, M.; Dusilova-Sulkova, S.; Zakiyanov, O.; Kostirova, M.; Safranek, R.; Tesar, V.; Zima, T. Vitamin D binding protein is not involved in vitamin D deficiency in patients with chronic kidney disease. Biomed Res. Int. 2015, 2015, 492365.
46. Nielsen, R.; Christensen, E. I.; Birn, H. Megalin and cubilin in proximal tubule protein reabsorption: From experimental models to human disease. Kidney Int. 2016, 89, 58–67.

506 47. Thrailkill, K. M.; Jo, C.-H.; Cockrell, G. E.; Moreau, C. S.; Fowlkes, J. L. Enhanced Excretion of Vitamin D
507 Binding Protein in Type 1 Diabetes: A Role in Vitamin D Deficiency? J. Clin. Endocrinol. Metab. 2011, 96, 142–
508 149.
509 48. Thrailkill, K. M.; Nimmo, T.; Bunn, R. C.; Cockrell, G. E.; Moreau, C. S.; Mackintosh, S.; Edmondson, R. D.;
510 Fowlkes, J. L. Microalbuminuria in type 1 diabetes is associated with enhanced excretion of the endocytic
511 multiligand receptors megalin and cubilin. Diabetes Care 2009, 32, 1266–8.
512 49. Leheste, J. R.; Melsen, F.; Wellner, M.; Jansen, P.; Schlichting, U.; Renner-Müller, I.; Andreassen, T. T.; Wolf,
513 E.; Bachmann, S.; Nykjaer, A.; Willnow, T. E. Hypocalcemia and osteopathy in mice with kidney-specific megalin
514 gene defect. FASEB J. 2003, 17, 247–9.
515 50. Seki, T.; Asanuma, K.; Asao, R.; Nonaka, K.; Sasaki, Y.; Trejo, J. A. O.; Kurosawa, H.; Hirayama, Y.; Horikoshi,
516 S.; Tomino, Y.; Saito, A. Significance of urinary full-length megalin in patients with IgA nephropathy. PLoS One
517 2014, 9, 1–15.
518 51. Gokal, R.; Ramos, J. M.; Ellis, H. A.; Parkinson, I.; Sweetman, V.; Dewar, J.; Ward, M. K.; Kerr, D. N.
519 Histological renal osteodystrophy, and 25 hydroxycholecalciferol and aluminum levels in patients on
520 continuous ambulatory peritoneal dialysis. Kidney Int. 1983, 23, 15–21.
521 52. Çankaya, E.; Bilen, Y.; Keleş, M.; Uyanik, A.; Akbaş, M.; Güngör, A.; Arslan; Aydinli, B. Comparison of Serum
522 Vitamin D Levels among Patients with Chronic Kidney Disease, Patients in Dialysis, and Renal Transplant
523 Patients. Transplant. Proc. 2015, 47, 1405–1407.
524 53. Lai, K. H.; Florence Tan, H. S.; Phui, V. E.; Chew, K. F.; Lawrence Hii, W. S.; Laura Ngu, L. S.; Lee, J.; Clare
525 Tan, H. H. A Study on the Prevalence of Serum 25(OH)-Vitamin D in Patients on Maintenance Hemodialysis
526 and Peritoneal Dialysis in Sarawak General Hospital. Kidney Int. Reports 2017, 2, S31.
527 54. Joffe, P.; Heaf, J. G. Vitamin D and vitamin-D-binding protein kinetics in patients treated with continuous
528 ambulatory peritoneal dialysis (CAPD). Perit.Dial.Int. 1989, 9, 281–284.
529 55. Shah, N.; Bernardini, J.; Piraino, B. Prevalence and correction of 25(OH) vitamin D deficiency in peritoneal
530 dialysis patients. Perit. Dial. Int. 2005, 25, 362–366.
531 56. Shany, S.; Rapoport, J.; Goligorsky, M.; Yankowitz, N.; Zuili, I.; Chaimovitz, C. Losses of 1,25- and 24,25-
532 dihydroxycholecalciferol in the peritoneal fluid of patients treated with continuous ambulatory peritoneal
533 dialysis. Nephron 1984, 36, 111–3.
534 57. Tarcin, O.; Yavuz, D. G.; Ozben, B.; Telli, A.; Ogunc, A. V.; Yuksel, M.; Toprak, A.; Yazici, D.; Sancak, S.;
535 Deyneli, O.; Akalin, S. Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic
536 subjects. J. Clin. Endocrinol. Metab. 2009, 94, 4023–30.
537 58. Carrara, D.; Bruno, R. M.; Bacca, A.; Taddei, S.; Duranti, E.; Ghiadoni, L.; Bernini, G. Cholecalciferol treatment
538 downregulates renin-angiotensin system and improves endothelial function in essential hypertensive patients
539 with hypovitaminosid D. J. Hypertens. 2016, 34, 2199–205.
540 59. Jablonski, K. L.; Chonchol, M.; Pierce, G. L.; Walker, A. E.; Seals, D. R. 25-Hydroxyvitamin D deficiency is
541 associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adults.
542 Hypertension 2011, 57, 63–69.
543 60. Alyami, A.; Soares, M. J.; Sherriff, J. L.; Mamo, J. C. Vitamin D & endothelial function. Indian J Med Res. 2014,
544 140, 483-90.
545 61. Li, Y. C.; Kong, J.; Wei, M.; Chen, Z. F.; Liu, S. Q.; Cao, L. P. 1,25-Dihydroxyvitamin D3 is a negative endocrine
546 regulator of the renin-angiotensin system. J. Clin. Invest. 2002, 110, 229–238.
547 62. Freundlich, M.; Quiroz, Y.; Zhang, Z.; Zhang, Y.; Bravo, Y.; Weisinger, J. R.; Li, Y. C.; Rodriguez-Iturbe, B.
548 Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int. 2008, 74, 1394–1402.
549 63. Yuan, W.; Pan, W.; Kong, J.; Zheng, W.; Szeto, F. L.; Wong, K. E.; Cohen, R.; Klopot, A.; Zhang, Z.; Li, Y. C.
550 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP
551 response element in the renin gene promoter. J. Biol. Chem. 2007, 282, 29821–29830.
552 64. Martins, D.; Wolf, M.; Pan, D.; Zadshir, A.; Tareen, N.; Thadhani, R.; Felsenfeld, A.; Levine, B.; Mehrotra, R.;
553 Norris, K. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United
554 States: Data from the Third National Health and Nutrition Examination Survey. Arch. Intern. Med. 2007, 167,
555 1159–1165.
556 65. Beveridge, L. A.; Struthers, A. D.; Khan, F.; Jorde, R.; Scragg, R.; Macdonald, H. M.; Alvarez, J. A.; Boxer, R.
557 S.; Dalbeni, A.; Gepner, A. D.; Isbel, N. M.; Larsen, T.; Nagpal, J.; Petchey, W. G.; Stricker, H.; Strobel, F.;
558 Tangpricha, V.; Toxqui, L.; Vaquero, M. P.; Wamberg, L.; Zittermann, A.; Witham, M. D. Effect of vitamin D

559 supplementation on blood pressure a systematic review and meta-analysis incorporating individual patient
560 data. JAMA Intern. Med. 2015, 175, 745–754.
561 66. Luchi, W. M.; Shimizu, M. H. M.; Canale, D.; Gois, P. H. F.; de Braganca, A. C.; Volpini, R. A.; Girardi, A. C.
562 C.; Seguro, A. C. Vitamin D deficiency is a potential risk factor for contrast-induced nephropathy. Am. J. Physiol.
563 Regul. Integr. Comp. Physiol. 2015, 309, R215-22.
564 67. de Braganca, A. C.; Volpini, R. A.; Canale, D.; Goncalves, J. G.; Shimizu, M. H. M.; Sanches, T. R.; Seguro, A.
565 C.; Andrade, L. Vitamin D deficiency aggravates ischemic acute kidney injury in rats. Physiol. Rep. 2015, 3,
566 e12331–e12331.
567 68. Canale, D.; De Bragança, A. C.; Gonçalves, J. G.; Shimizu, M. H. M.; Sanches, T. R.; Andrade, L.; Volpini, R.
568 A.; Seguro, A. C. Vitamin D deficiency aggravates nephrotoxicity, hypertension and dyslipidemia caused by
569 tenofovir: Role of oxidative stress and renin-angiotensin system. PLoS One 2014, 9.
570 69. Codoñer-Franch, P.; Tavárez-Alonso, S.; Simó-Jordá, R.; Laporta-Martín, P.; Carratalá-Calvo, A.; Alonso-
571 Iglesias, E. Vitamin D Status is Linked to Biomarkers of Oxidative Stress, Inflammation, and Endothelial
572 Activation in Obese Children. J. Pediatr. 2012, 161, 848–854.
573 70. Hewison, M. Antibacterial effects of vitamin D. Nat. Rev. Endocrinol. 2011, 7, 337–345.
574 71. Wang, T.-T.; Nestel, F. P.; Bourdeau, V.; Nagai, Y.; Wang, Q.; Liao, J.; Tavera-Mendoza, L.; Lin, R.; Hanrahan,
575 J. H.; Mader, S.; White, J. H. Cutting Edge: 1,25-Dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide
576 gene expression. J. Immunol. 2004, 173, 2909–2912.
577 72. Fritsche, J.; Mondal, K.; Ehrnsperger, A.; Andreesen, R.; Kreutz, M. Regulation of 25-hydroxyvitamin D3-1
578 alpha-hydroxylase and production of 1 alpha,25-dihydroxyvitamin D3 by human dendritic cells. Blood 2003,
579 102, 3314-6.
580 73. Yu, X. P.; Bellido, T.; Manolagas, S. C. Down-regulation of NF-kappa B protein levels in activated human
581 lymphocytes by 1,25-dihydroxyvitamin D3. Proc. Natl. Acad. Sci. U. S. A. 1995, 92, 10990–4.
582 74. Hewison, M. Vitamin D and the Immune System: New Perspectives on an Old Theme. Endocrinol. Metab.
583 Clin. North Am. 2010, 39, 365–379.
584 75. Chen, S.; Sims, G. P.; Chen, X. X.; Gu, Y. Y.; Chen, S.; Lipsky, P. E. Modulatory effects of 1,25-
585 dihydroxyvitamin D3 on human B cell differentiation. J. Immunol. 2007, 179, 1634–47.
586 76. Provvedini, D. M.; Tsoukas, C. D.; Deftos, L. J.; Manolagas, S. C. 1 alpha,25-Dihydroxyvitamin D3-binding
587 macromolecules in human B lymphocytes: effects on immunoglobulin production. J. Immunol. 1986, 136, 2734–
588 40.
589 77. Mucsi, I.; Almási, C.; Deák, G.; Marton, A.; Ambrus, C.; Berta, K.; Lakatos, P.; Szabó, A.; Horváth, C. Serum
590 25(OH)-vitamin D levels and bone metabolism in patients on maintenance hemodialysis. Clin. Nephrol. 2005,
591 64, 288–94.
592 78. Milinković, N. L.; Majkić-Singh, N. T.; Mirković, D. D.; Beletić, A. D.; Pejanović, S. D.; Vujanić, S. T. Relation
593 between 25(OH)-vitamin D deficiency and markers of bone formation and resorption in haemodialysis patients.
594 Clin. Lab. 2009, 55, 333–9.
595 79. Kandula, P.; Dobre, M.; Schold, J. D.; Schreiber, M. J.; Mehrotra, R.; Navaneethan, S. D. Vitamin D
596 Supplementation in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Observational Studies
597 and Randomized Controlled Trials. Clin. J. Am. Soc. Nephrol. 2011, 6, 50–62.
598 80. Palmer, S. C.; McGregor, D. O.; Craig, J. C.; Elder, G.; Macaskill, P.; Strippoli, G. F. M. Vitamin D compounds
599 for people with chronic kidney disease not requiring dialysis Cochrane Database Syst Rev. 2009, 4, CD008175.
600 81. Palmer, S. C.; McGregor, D. O.; Craig, J. C.; Elder, G.; Macaskill, P.; Strippoli, G. F. Vitamin D compounds for
601 people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev. 2009, 4, CD005633.
602 82. Moe, S. M.; Saifullah, A.; LaClair, R. E.; Usman, S. A.; Yu, Z. A randomized trial of cholecalciferol versus
603 doxercalciferol for lowering parathyroid hormone in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2010, 5,
604 299–306.
605 83. Urea-Torres, P.; Metzger, M.; Haymann, J. P.; Karras, A.; Boffa, J. J.; Flamant, M.; Vrtovsnik, F.; Gauci, C.;
606 Froissart, M.; Houillier, P.; Stengel, B. Association of kidney function, vitamin D deficiency, and circulating
607 markers of mineral and bone disorders in CKD. Am. J. Kidney Dis. 2011, 58, 544–553.
608 84. Yadav, A. K.; Kumar, V.; Kumar, V.; Banerjee, D.; Gupta, K. L.; Jha, V. The Effect of Vitamin D
609 Supplementation on Bone Metabolic Markers in Chronic Kidney Disease. J Bone Miner Res. 2018, 33, 404-409.
610 85. Lee, Y.; Kim, J. E.; Roh, Y. H.; Choi, H. R.; Rhee, Y.; Kang, D. R.; Lim, S.-K. The Combination of Vitamin D
611 Deficiency and Mild to Moderate Chronic Kidney Disease Is Associated with Low Bone Mineral Density and

612 Deteriorated Femoral Microarchitecture: Results from the KNHANES 2008–2011. J. Clin. Endocrinol. Metab.
613 2014, 99, 3879–3888.
614 86. Coen, G.; Mantella, D.; Manni, M.; Balducci, A.; Nofroni, I.; Sardella, D.; Ballanti, P.; Bonucci, E. 25-
615 hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy. Kidney Int. 2005,
616 68, 1840–1848.
617 87. Dey, V.; Farrah, T. E.; Traynor, J. P.; Spalding, E. M.; Robertson, S. E.; Geddes, C. C. Symptomatic fracture
618 risk in the renal replacement therapy population. Nephrol. Dial. Transplant. 2017, 32, 1211-6.
619 88. Bataille, S.; Landrier, J.-F.; Astier, J.; Giaime, P.; Sampol, J.; Sichez, H.; Ollier, J.; Gugliotta, J.; Serveaux, M.;
620 Cohen, J.; Darmon, P. The "Dose-Effect" Relationship Between 25-Hydroxyvitamin D and Muscle Strength in
621 Hemodialysis Patients Favors a Normal Threshold of 30 ng/mL for Plasma 25-Hydroxyvitamin D. J. Ren. Nutr.
622 2016, 26, 45–52.
623 89. Boudville, N.; Inderjeeth, C.; Elder, G.; Glendenning, P. Association between 25-hydroxyvitamin D, somatic
624 muscle weakness and falls risk in end-stage renal failure. Clin. Endocrinol. (Oxf). 2010, 73, 299–304.
625 90. Verrotti, A.; Basciani, F.; Carle, F.; Morgese, G.; Chiarelli, F. Calcium metabolism in adolescents and young
626 adults with type 1 diabetes mellitus without and with persistent microalbuminuria. J Endocrinol Invest 1999, 22,
627 198–202.
628 91. Inukai, T.; Fujiwara, Y.; Tayama, K.; Aso, Y.; Takemura, Y. Alterations in serum levels of 1 alpha,25(OH)2 D3
629 and osteocalcin in patients with early diabetic nephropathy. Diabetes Res. Clin. Pract. 1997, 38, 53–9.
630 92. Damasiewicz, M. J.; Magliano, D. J.; Daly, R. M.; Gagnon, C.; Lu, Z. X.; Sikaris, K. A.; Ebeling, P. R.; Chadban,
631 S. J.; Atkins, R. C.; Kerr, P. G.; Shaw, J. E.; Polkinghorne, K. R. Serum 25-hydroxyvitamin D deficiency and the 5-
632 year incidence of CKD. Am. J. Kidney Dis. 2013, 62, 58–66.
633 93. Li, Y. C.; Qiao, G.; Uskokovic, M.; Xiang, W.; Zheng, W.; Kong, J. Vitamin D: A negative endocrine regulator
634 of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol. 2004, 89-90, 387-92.
635 94. Resnick, L. M.; Müller, F. B.; Laragh, J. H. Calcium-regulating hormones in essential hypertension. Relation
636 to plasma renin activity and sodium metabolism. Ann Intern Med. 1986, 105, 649-54.
637 95. Rüster, C.; Wolf, G. Renin-angiotensin-aldosterone system and progression of renal disease. J. Am. Soc.
638 Nephrol. 2006, 17, 2985-91.
639 96. Sun, J.; Kong, J.; Duan, Y.; Szeto, F. L.; Liao, A.; Madara, J. L.; Li, Y. C. Increased NF-kappaB activity in
640 fibroblasts lacking the vitamin D receptor. Am. J. Physiol. Endocrinol. Metab. 2006, 291, E315-22.
641 97. Takemoto, F.; Shinki, T.; Yokoyama, K.; Inokami, T.; Hara, S.; Yamada, A.; Kurokawa, K.; Uchida, S. Gene
642 expression of vitamin D hydroxylase and megalin in the remnant kidney of nephrectomized rats. Kidney Int.
643 2003, 64, 414-20
644 98. Molina, P.; Górriz, J. L.; Molina, M. D.; Peris, A.; Beltrán, S.; Kanter, J.; Escudero, V.; Romero, R.; Pallardó, L.
645 M. The effect of cholecalciferol for lowering albuminuria in chronic kidney disease: A prospective controlled
646 study. Nephrol. Dial. Transplant. 2014, 29, 97–109.
647 99. Kim, M. J.; Frankel, A. H.; Donaldson, M.; Darch, S. J.; Pusey, C. D.; Hill, P. D.; Mayr, M.; Tam, F. W. K. Oral
648 cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on
649 established renin-angiotensin- aldosterone system inhibition. Kidney Int. 2011, 80, 851–860.
650 100. Ross, A. C.; Manson, J. E.; Abrams, S. A.; Aloia, J. F.; Brannon, P. M.; Clinton, S. K.; Durazo-Arvizu, R. A.;
651 Gallagher, J. C.; Gallo, R. L.; Jones, G.; Kovacs, C. S.; Mayne, S. T.; Rosen, C. J.; Shapses, S. A. The 2011 Report on
652 Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to
653 Know. J. Clin. Endocrinol. Metab. 2011, 96, 53–58.
654 101. Chan, A. M.; Johnson, D. Vitamin D therapy (supplementation) in early chronic kidney disease. The CARI
655 guidelines. http://www.cari.org.au/CKD/CKD%20early/Vitamin_D_Therapy_ECKD.pdf (accessed on 17 July
656 2018).
657 102. Holick, M. F.; Biancuzzo, R. M.; Chen, T. C.; Klein, E. K.; Young, A.; Bibuld, D.; Reitz, R.; Salameh, W.; Ameri,
658 A.; Tannenbaum, A. D. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-
659 hydroxyvitamin D. J. Clin. Endocrinol. Metab. 2008, 93, 677–681.
660 103. Bikle, D. D. Vitamin D metabolism, mechanism of action, and clinical applications. Chem. Biol. 2014, 21,
661 319–29.
662 104. Armas, L. A. G.; Hollis, B. W.; Heaney, R. P. Vitamin D2 is much less effective than vitamin D3 in humans.
663 J. Clin. Endocrinol. Metab. 2004, 89, 5387–5391.
664 105. Houghton, L. A.; Vieth, R. The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am. J. Clin.
665 Nutr. 2006, 84, 694-7.

666 106. Holmberg, I.; Berlin, T.; Ewerth, S.; Björkhem, I. 25-hydroxylase activity in subcellular fractions from human
667 liver. Evidence for different rates of mitochondrial hydroxylation of vitamin d2and d3. Scand. J. Clin. Lab. Invest.
668 1986, 46, 785-90.
669 107. Hollis, B. W. Comparison of equilibrium and disequilibrium assay conditions for ergocalciferol,
670 cholecalciferol and their major metabolites. J. Steroid Biochem. 1984.
671 108. Haddad, J. G.; Matsuoka, L. Y.; Hollis, B. W.; Hu, Y. Z.; Wortsman, J. Human plasma transport of vitamin
672 D after its endogenous synthesis. J. Clin. Invest. 1993, 91, 2552-5.
673 109. Hoy, D. A.; Ramberg, C. F.; Horst, R. L. Evidence that discrimination against ergocalciferol by the chick is
674 the result of enhanced metabolic clearance rates for its mono- and dihydroxylated metabolites. J. Nutr. 1988, 118,
675 633-8.
676 110. Tripkovic, L.; Lambert, H.; Hart, K.; Smith, C. P.; Bucca, G.; Penson, S.; Chope, G.; Berry, J.; Vieth, R.;
677 Lanham-new, S. Comparison of vitamin D 2 and vitamin D 3 supplementation in raising serum 25-
678 hydroxyvitamin D status: a systematic review. Am. J. Clin. Nutr. 2012, 95, 1357–1364.
679 111. Institute of Medicine of the National Academices. Dietary Reference Intakes for Calcium and Vitamin D;
680 National Academies Press: Washington, DC, USA, 2011.
681